The company believes that “they are the first to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity upon receiving final FDA approval.”
International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences’ hepatitis C drug Sofosbuvir at the European Patent Office in order to increase access to the treatment.